Literature DB >> 20632887

Human cytomegalovirus induces systemic immune activation characterized by a type 1 cytokine signature.

Pablo J van de Berg1, Kirstin M Heutinck, Robin Raabe, Robert C Minnee, Si La Young, Karlijn A van Donselaar-van der Pant, Frederike J Bemelman, Rene A van Lier, Ineke J ten Berge.   

Abstract

Mechanisms underlying the onset and perpetuation of chronic immune activation in individuals without overt infectious or autoimmune diseases are unclear. Cytomegalovirus (CMV) is a persistent virus that induces a permanent increase of highly differentiated, interferon-gamma-secreting effector T cells. We hypothesized that, because of this increase, CMV also induces a systemic inflammatory response. We measured acute phase proteins, cytokines, and chemokines in serum samples from renal transplant recipients who developed a primary CMV infection and healthy CMV serum-positive or -negative individuals. Primary CMV infection induced a clear proinflammatory response that was maintained during latency. This response was characterized by increased levels of acute phase proteins, such as serum amyloid-A and C-reactive protein, and type 1 cytokines, such as interleukin-18, interferon-inducible protein-10, and interferon-gamma. This continuous activation of the immune system may play a role in the pathogenesis of chronic allograft rejection and potentially contribute to the acceleration of chronic diseases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20632887     DOI: 10.1086/655472

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  65 in total

1.  Role of cytomegalovirus on the maturation and function of monocyte derived dendritic cells of liver transplant patients.

Authors:  Mohammad Hossein Karimi; Afsoon Shariat; Ramin Yaghobi; Talat Mokhtariazad; Seyed Mohammad Moazzeni
Journal:  World J Transplant       Date:  2016-06-24

2.  Infections in liver transplant recipients.

Authors:  Fabian A Romero; Raymund R Razonable
Journal:  World J Hepatol       Date:  2011-04-27

3.  Not just leukemia: CMV may protect against lymphoma recurrence after allogeneic transplant.

Authors:  Jonathan U Peled; Robert R Jenq
Journal:  Leuk Lymphoma       Date:  2016-10-12

Review 4.  Kidney transplantation and the ageing immune system.

Authors:  Dianne McKay; Julie Jameson
Journal:  Nat Rev Nephrol       Date:  2012-11-13       Impact factor: 28.314

5.  Primary response against cytomegalovirus during antiviral prophylaxis with valganciclovir, in solid organ transplant recipients.

Authors:  Corinna La Rosa; Ajit P Limaye; Aparna Krishnan; Gideon Blumstein; Jeff Longmate; Don J Diamond
Journal:  Transpl Int       Date:  2011-06-14       Impact factor: 3.782

6.  Autoimmune-like syndromes during TNF blockade: does infection have a role?

Authors:  Joerg C Prinz
Journal:  Nat Rev Rheumatol       Date:  2011-03-29       Impact factor: 20.543

Review 7.  Chronic kidney disease and premature ageing of the adaptive immune response.

Authors:  Michiel G H Betjes; Nicolle H R Litjens
Journal:  Curr Urol Rep       Date:  2015-01       Impact factor: 3.092

8.  Kaposi's sarcoma-associated herpesvirus latency in endothelial and B cells activates gamma interferon-inducible protein 16-mediated inflammasomes.

Authors:  Vivek Vikram Singh; Nagaraj Kerur; Virginie Bottero; Sujoy Dutta; Sayan Chakraborty; Mairaj Ahmed Ansari; Nitika Paudel; Leela Chikoti; Bala Chandran
Journal:  J Virol       Date:  2013-02-06       Impact factor: 5.103

9.  Altered CD4+ T cell immunity in nurses occupationally exposed to viral pathogens.

Authors:  G Elias; A Souquette; S Heynderickx; I De Meester; H Jansens; P Beutels; P Van Damme; E Smits; P G Thomas; V Van Tendeloo; B Ogunjimi
Journal:  Clin Exp Immunol       Date:  2018-09-19       Impact factor: 4.330

Review 10.  Understanding and controlling chronic immune activation in the HIV-infected patients suppressed on combination antiretroviral therapy.

Authors:  Babafemi Taiwo; Luis Barcena; Randall Tressler
Journal:  Curr HIV/AIDS Rep       Date:  2013-03       Impact factor: 5.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.